Entrada Therapeutics (TRDA) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $17.00 from $20.00 | Jun 8, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | May 8, 2026 |
| Oppenheimer | Maintained | Outperform | $23.00 from $21.00 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Feb 18, 2026 |
| Guggenheim | Initiated Coverage | Buy | $20.00 | Feb 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | May 20, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Mar 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Feb 25, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Feb 4, 2025 |
| Roth MKM | Initiated Coverage | Buy | $29.00 | Dec 5, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $18.00 | Nov 6, 2024 |
| Oppenheimer | Maintained | Outperform | $28.00 from $25.00 | Nov 6, 2024 |
| Oppenheimer | Maintained | Outperform | $25.00 | Aug 26, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Aug 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $20.00 | Jun 25, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Mar 18, 2024 |
| Oppenheimer | Initiated Coverage | Outperform | $22.00 | Jan 5, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $25.00 | Nov 27, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Sep 22, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Aug 9, 2023 |
Frequently asked questions
Is TRDA a buy, sell, or hold?
Analysts covering Entrada Therapeutics currently average a Buy rating: 6 buy, 1 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on TRDA?
On Jun 8, 2026, Guggenheim maintained Entrada Therapeutics at Buy with a price target of $17.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.